VRAYQ vs. NOVN, NOVNQ, AHPI, GNCA, HTGMQ, STAB, SCPS, IGNY, VIVE, and TIVC
Should you be buying ViewRay stock or one of its competitors? The main competitors of ViewRay include Novan (NOVN), NVN Liquidation (NOVNQ), Allied Healthcare Products (AHPI), Genocea Biosciences (GNCA), HTG Molecular Diagnostics (HTGMQ), Statera Biopharma (STAB), Scopus BioPharma (SCPS), Ignyte Acquisition (IGNY), Viveve Medical (VIVE), and Tivic Health Systems (TIVC). These companies are all part of the "medical" sector.
Novan (NASDAQ:NOVN) and ViewRay (NASDAQ:VRAYQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings, dividends and community ranking.
14.5% of Novan shares are held by institutional investors. Comparatively, 15.5% of ViewRay shares are held by institutional investors. 1.3% of Novan shares are held by insiders. Comparatively, 2.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Novan received 239 more outperform votes than ViewRay when rated by MarketBeat users.
ViewRay has a net margin of 0.00% compared to ViewRay's net margin of -128.61%. Novan's return on equity of 0.00% beat ViewRay's return on equity.
In the previous week, Novan had 1 more articles in the media than ViewRay. MarketBeat recorded 1 mentions for Novan and 0 mentions for ViewRay. ViewRay's average media sentiment score of 0.00 equaled Novan'saverage media sentiment score.
Novan has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.
Novan has higher earnings, but lower revenue than ViewRay.
Summary
ViewRay beats Novan on 8 of the 11 factors compared between the two stocks.
Get ViewRay News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRAYQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VRAYQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VRAYQ vs. The Competition
Related Companies and Tools
